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Serum amyloid A (SAA) acts as a major acute phase protein and represents a sensitive and accurate marker of inﬂammation.
Besides its hepatic origin, as the main source of serum SAA, this protein is also produced extrahepatically. The mRNA levels
of SAA become signiﬁcantly elevated following proinﬂammatory stimuli, as well as, are induced through their own positive
feedback in human primary coronary artery endothelial cells. However, the intracellular functions of SAA are so far unknown.
Colocalization of SAA with cytoskeletal ﬁlaments has previously been proposed, so we analyzed the colocalization of SAA with all
three cytoskeletal elements: actin ﬁlaments, vimentin ﬁlaments, and microtubules. Immunoﬂuorescent double-labeling analyses
conﬁrmed by PLA method revealed a strict colocalization of SAA with microtubules and a very infrequent attachment to vimentin
while the distribution of actin ﬁlaments appeared clearly separated from SAA staining. Also, no signiﬁcant colocalization was
found between SAA and endomembranes labeled with the ﬂuorescent lipid stain DiO6. However, SAA appears to be located also
unbound in the cytosol, as well as inside the nucleus and within nanotubes extending from the cells or bridging neighboring cells.
These diﬀerent locations of SAA in endothelial cells strongly indicate multiple potential functions of this protein.
1.Introduction
The acute phase response represents an evolutionarily con-
served mechanism of inﬂammatory events designed to
rapidly react to infections, wounds, and injuries. It can lead
to a dramatic increase (up to 1000 fold) in the levels of acute
phase proteins (APPs) in the circulation and, ultimately,
brings about resolution of the inﬂammatory reaction [1, 2].
Serum amyloid A (SAA) one of the major APPs in humans is
mainlyproducedbytheliver,althoughextrahepaticsynthesis
is also prevalent [3].
SAA originates from an evolutionarily conserved multi-
gene family [4] ranging from invertebrates (with a wound-
healing role in sea cucumbers [5]), vertebrates, to humans,
where it represents an accurate and sensitive marker of inﬂa-
mmation [2]. Human SAA1 and SAA2 are the inducible iso-
types (addressed jointly as SAA1/2, with over 95% sequence
identity); SAA3, was thought in the past to be a pseudogene,
not expressed in humans; however, recently there has been a
report of its mammary-associated expression found in milk
[6]. SAA4 was found to be the constitutively expressed iso-
type [4]. There have been three acute phase SAA isotypes
reported in the mouse SAA1, SAA2, and SAA3, with SAA3
being the primarily extrahepatic isoform [7]. SAA is a small
protein (104 amino acids in length), 11.7kDa in size, lipo-
philic, and poorly soluble in aqueous solution, originally
described as a component of normal serum [8]. SAA frag-
ments were found in amyloidosis, and the accumulation of
theseﬁbrilscanleadtoorganfailureandultimatelydeath[9].
Murine and human SAA have been shown to form hexamers
in solution, which can lead to the formation of membrane
channels that could be involved in important pathological
roles [10, 11].
SAA1/2 has a variety of multiple functions in humans,
among them it acts as a cytokine and chemokine, induces
matrix metalloproteinases, interferes with platelet functions,
replaces Apo-A1 in high density lipoprotein particles in
the circulation during inﬂammation, binds cholesterol and2 Journal of Biomedicine and Biotechnology
inﬂuences its eﬄux, and plays a role in host defense [10,
12–18]. In physiological concentrations (∼100–200nM as
measured in sera), SAA is thought to act in homeostasis of
inﬂammatory events, while at prolonged higher pathological
concentrations(above1000nM)SAAcouldactinadegrada-
tivemannercausinginjurytotissuesandcellsduringchronic
inﬂammatory conditions. The expression of SAA has also
been shown in nonhepatic epithelial cells and can play a role
in tumorigenesis [19]. Its ability to opsonize Gram-negative
bacteria could contribute to the epithelial defense mecha-
nism against these bacteria [15].
SAA is measured routinely in sera or plasma in the veter-
inary ﬁeld (especially useful in equine [20], bovine, porcine,
andalsobirdandﬁshpathologies)andhasproventobearel-
evant biomarker and predictor of many diseases in humans
(among them cardiovascular diseases [21]). SAA was identi-
ﬁed as an independent risk predictor of mortality following
acute myocardial infarction [22] and indicated to play a
causal role in atherogenesis [23, 24]. SAA mRNA expression
hasbeenlocalizedtomanydiﬀerenthumantissues,including
atheroscleroticplaques,whereSAAproteinisthoughttoplay
anactivepathogenicrole[7].Some of thestrongestsignals in
this study were observed in endothelial cells lining the lumen
of coronary arteries and in macrophage-derived “foam cells.”
The expression of SAA mRNA within cultured human
primary coronary artery endothelial cells (HCAEC) was ﬁrst
reported in 2007 [25] and these cells were also shown to
be highly responsive to human recombinant SAA1/2, as an
inﬂammatory stimulus, indicating a strong positive feedback
onto its own synthesis. However, very little is known about
thelocalization ofSAAwithinthesecells,whetheritis releas-
ed and could act locally at the extracellular level or SAA
remains in HCAEC and could inﬂuence endothelial function
in an intracellular manner.
So, our objective was to determine the localization of
intracellular SAA in HCAEC and to elucidate possible asso-
ciations of SAA with particular cytoskeletal elements.
2.MaterialsandMethods
2.1. Materials. Rabbit anti-SAA polyclonal antibodies were a
gift from Professor Ernst Malle (Institute of Molecular Bio-
logy and Biochemistry, Medical University of Graz, Austria).
The anti-SAA antibodies used for the immunoﬂuorescent
staining were raised against synthetic peptides of SAA rang-
ing from the indicated amino acid sequences: 27–44 (pAb
3), 59–72 (pAb 5), and 68–84 (pAb 6). For the immunoblot
analysis, eight separate anti-SAA polyclonal antibodies were
used,ranginginconsecutiveorder,asraisedagainstsynthetic
SAA peptides from pAb 1 to pAb 8. (SAA 1–17, SAA 14–30,
SAA 27–44, SAA 40–63, SAA 59–72, SAA 68–84, SAA 79–94,
SAA 89–104, resp.).
2.2. Cell Culture. HCAEC were purchased from Lonza
(Walkersville, USA). Cells were cultured in EGM-2M med-
ium (Lonza, Walkesville, USA) containing 5% fetal bovine
serum at 37◦C in a humidiﬁed atmosphere and 5% CO2.
Forimmunoﬂuorescentstaining,HCAECwereusedthrough
passage 5 of subconﬂuent (80–85% conﬂuency) cell cultures.
2.3. Fluorescent Labeling of Cells. Cells were ﬁxed in 4%
paraformaldehyde for 30 min at 37◦C, then washed in PBS.
For actin staining, cells were labelled with phalloidin-
ﬂuorescein isothiocyanate (FITC) (2μM in 20% methanol)
(Sigma, Germany).
For SAA, α-tubulin, and vimentin, cells were incubated
with rabbit antibodies against SAA and/or mouse antibody
against vimentin (Dako, USA) or α-tubulin (Sigma, Ger-
many) and with the appropriate secondary antibodies conju-
gated with FITC or TRITC (Sigma, Germany). The Von
Willebrandfactorwasdeterminedwithimmunoﬂuorescence
microscopy (Abcam, Cambridge, Great Britain).
For labelling of endomembranes, a lipophilic stain 3,3 -
dihexyloxacarbocyanin iodide (DiO6) was used. It mainly
labels endoplasmic reticulum and mitochondria (Molecular
Probes manual). A stock solution of membrane marker vib-
rantDiO6 (0.5mg DiO6/mL ethanol) (Invitrogen, Molecular
Probes,Leiden,TheNetherlands)wasfreshlyprepared,anda
0.5% dilution of DiO6 in culture medium was added to cells
for3min.AfterwashinginPBS,thecoverslipswithcellswere
embedded with antibleaching medium Vectashield contain-
ing the nuclear stain diamidinophenylindole dilactate
(DAPI) (Vector Laboratories, Burlingame, Calif, USA) and
observed with a ﬂuorescence microscopes (Nikon eclipse TE
300 and AxioImager Z1, Carl Zeiss) supplemented with Apo
Tome device for generation of optical sections.
2.4.InSituProximityLigationAssay(PLA). Inordertodeter-
mine the colocalization between SAA and MT, SAA and
VIM,thePLAassay(OlinkBioscience,Uppsala,Sweden)was
performed according to the manufacturer’s protocol. In
brief, ﬁxation, permeabilization, blockade, and incubation
with primary antibodies were performed as described in the
Section 2.3. Subsequently, the cells were incubated with the
secondary mouse PLUS and rabbit MINUS antibodies. After
hybridization and ligation of the oligonucleotides, the DNA
was ampliﬁed by addition of an ampliﬁcation mixture. A
detection mixture detected the amplicons resulting in red
ﬂuorescence signals. In the ﬁnal step, the nuclei were coun-
terstained with DAPI and the cells were mounted with
mounting medium (Vector Laboratories, Burlingame, Calif,
USA). As a control, the cells were incubated without pri-
mary antibodies. Cells were analyzed with a 63x objective on
a ﬂuorescent microscope AxioImager Z1 (Carl Zeiss) sup-
plemented with ApoTome device for optical sections genera-
tion.
2.5. Immunoblots. Human recombinant SAA (5.3μg/cm gel)
(PeproTech Ec Ltd., London, UK) was loaded onto SDS-
PAGE. After transfer to nitrocellulose membranes (100V,
250mA, 35min), blocking was performed in TBS with 5%
milk. As primary antibodies, polyclonal rabbit anti-SAA
antibodies were used (gift of prof. Malle) in a 1:1000 dilu-
tion for 2hrs. Following washing, secondary incubation was
done with antirabbit HRP conjugate (Biorad, Munich, Ger-
many) at 1:200 dilution with subsequent Western blot lumi-
nol reagent (Santa Cruz, Calif, USA) and chemiluminescent
detection performed following manufacturer’s instructions.Journal of Biomedicine and Biotechnology 3
3. Results
InordertodeterminethedistributionofSAAwithinHCAEC
and its colocalization with cytoskeletal elements, endomem-
branes, and the nucleus, ﬂuorescent labeling of these
components was performed in spread nonconﬂuent cells.
To conﬁrm the endothelial nature of these cells, the Von
Willebrand factor was determined (Figure 1(a)).
3.1. Cytoskeleton. Labeling of SAA together with phalloidin
conﬁrmed that the majority of actin ﬁlaments were at the
cell periphery and clearly separated from the location of
SAA which is mainly concentrated in the central part of
the cells (Figure 1(b)). Vimentin was organized as a network
spreading from the nuclear region toward the cell periphery
and was generally distributed in the same cell area as SAA.
However, double labeling of vimentin and SAA revealed
a rare colocalization of the two signals and thus gave a
very low probability for their codistribution (Figure 1(d))
with antivimentin. The labeling of SAA in many locations,
especially in the cell periphery of HCAEC cells, largely ﬁts
in with the linear pattern of microtubular labeling providing
a high probability for the actual colocalization with this
cytoskeletal component (Figure 1(c)). The attachment of
SAA to microtubules is limited to small spots of SAA label-
ingwhilelargerclumpsofSAA(couldbepossiblemultimeri-
zationofSAA)appeartobenonattachedtoanyofthelabeled
structures (Figure 1(e)).
To evaluate the data showing colocalization by double
labeling of SAA with microtubules and vimentin ﬁlaments,
we performed the PLA method demonstrating close proxim-
ity of labeled proteins (maximum distance between proteins
that still enables reaction is 30nm). The strong reaction
product conﬁrmed the colocalization of SAA and tubulin
(Figure 1(g)) while a weak reaction product in the case of
SAA and vimentin (Figure 1(h)) makes speciﬁc colocaliza-
tion very improbable. The negative control by omitting pri-
mary antibodies gave a completely negative result (data not
shown).
3.2. Nucleus. Often the strongest SAA staining was observed
in the nucleus (Figures 2(a) and 2(a’)) and in the area close-
ly surrounding the nucleus where the majority of endomem-
branes are concentrated (Figure 2(c)). To ﬁnd out if SAA
colocalizes with endomembranes, especially endoplasmic
reticulum, Golgi apparatus, or transport vesicles, endomem-
branes were labeled with a lipophilic stain DiO6 that pref-
erentially labels membranes of the endomembrane system
and the mitochondrial membranes (Figures 2(b) and 2(c)).
The double labeling of DiO6 with SAA did not show any
speciﬁc colocalization of the two labels making functional
connection of SAA to endomembranes doubtful.
3.3. Communication. Surprisingly, intense labeling of SAA
was found in tubular protrusions extending from the cells
(Figure 2(d)). SAA was found at the tips of shorter exten-
sions, probably ﬁlopodia, and also in longer nanotubes
bridging neighboring cells. Occasionally, SAA labeling was
detectedindilatationsofnanotubes(whitearrows)described
as gondolas in our previous work [26] and in extracellular
membrane vesicles of cells that were attached to the bottom
of the tissue culture dishes, labeled with DiO6 (white arrow-
heads).
3.4. Multimerization. In order to determine potential mul-
timerization of SAA, polyclonal anti-SAA antibodies against
speciﬁc human synthetically derived SAA peptides were test-
ed on immunoblots. Anti-SAA antibodies bound to diﬀerent
multimers of SAA following immunoblotting (Figure 3),
including dimers, trimers, and higher multimers.
Anti-SAA antibodies against SAA peptides 1, 4, and 7
gave a similar pattern on the immunoblots, with a strong sig-
nal around 20kD, whereas anti-SAA antibodies against SAA
peptides 3, 5, 6, and 8 gave the strongest monomer band
signal, with higher bands appearing also at multimers and
potentially indicating conformational epitopes. The anti-
body directed against SAA peptide 2 gave only one high
multimer signal.
4. Discussion
The cellular localization and potential functions of SAA are
largely unknown in extrahepatic tissues.
To determine the location of SAA in endothelial cells,
HCAEC were double labeled for codistribution of this pro-
tein with cytoskeletal elements, endomembranes, and nu-
cleus. There was no apparent colocalization of SAA found
with either actin ﬁlaments and very rare with vimentin
(Figures 1(b) and 1(d)). However, this paper is the ﬁrst,
to our knowledge, indicating colocalization of SAA with
microtubules in HCAEC (Figures 1(c) and 1(e)). The colo-
calization was further conﬁrmed with the PLA method indi-
cating the distance of less than 30nm for the two proteins (as
evaluated and conﬁrmed by the manufacturer) between SAA
and tubulin. The PLA method has recently been determined
as comparable to FRET (ﬂuorescence resonance energy
transfer) method in case of semiquantitative and qualitative
analysis [27]. The positive reaction with PLA makes it rather
unlikely for SAA to be located inside any transport vesicles
attached to microtubules by motor proteins, because in this
case, the distance should largely exceed the maximum value
enabling the reaction and even more the vesicle membrane
would probably prevent the ligation process required for the
reaction product to form. In conclusion, SAA seems to be
directly attached to microtubules giving this protein a new
potential role as a cytosolic protein distinct from the already
known secretory version of this protein, which is mainly
found in the serum.
Few studies to date have addressed the intracellular local-
ization of SAA. In the 1970s, SAA-like protein had been
detectedusinganti-SAAantibodiesinhumanplacentae.SAA
localized to the cytoplasm of cells within the mesenchymal
stroma (thought to be ﬁbroblasts), to fetal stem vessel endo-
thelium, and to perivascular tissue. SAA had been shown
to be localized to 10nm intermediate ﬁlaments which form
characteristic perinuclear bundles following treatment with4 Journal of Biomedicine and Biotechnology
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(a)
SAA + ACT
(b)
SAA-MT
(c)
SAA-VIM
(d)
OS: SAA-MT
(e)
OS: SAA-VIM
(f)
DL: SAA-TUB
(g)
DL: SAA-VIM
(h)
Figure 1:SAAlocalizeswithmicrotubulesinuntreatedHCAEC,butnotwithactinﬁlamentsorvimentin.InHCAECVonWillebrandfactor
(vWB) is demonstrated (red) in all cells (a). In (b) labeling of actin ﬁlaments, SAA, and nuclei is presented. In (c) (stack of optical sections)
and (e) (larger magniﬁcation) SAA labeling can be detected attached to microtubules MT (arrowheads). Vimentin labeling together with
SAA does not show any speciﬁc colocalization ((d)—stack of optical sections and (f) larger magniﬁcation). In (b, c, d, e and f) the labeling
of SAA is red, of cytoskeletal elements is green, nuclei is blue. With PLA method colocalization of SAA with tubulin ((g)-TUB) or with
vimentin ((h)-VIM) resulted in red reaction product strongly expressed only for tubulin and SAA. Anti-SAA polyclonal antibodies 3, 5, and
6, which target SAA peptides with amino acid sequences 27–44, 59–72, and 68–84, respectively, were used in the designated SAA panels. Bar
= 10 μm.Journal of Biomedicine and Biotechnology 5
SAA
(a)
SAA + DAPI
10µm
SAA + DiO6
1µm
(b)
SAA + DiO6 + DAPI
5µm
(c)
SAA + DiO6
5µm
(d)
(a)
Figure 2: Staining for SAA is found in the nucleus, nanotubes, and budding vesicles; however, its association with endomembranes remains
unclear. SAA in HCAEC shows a predominantly nuclear localization, with a strong signal also concentrated in the juxta-nuclear cytoplasm
(a ). In (a) and (a ) the cut views above and on the right of each panel represents the SAA mainly inside nuclei and in the perinuclear space.
In HCAEC nuclei were stained with DAPI (blue), endomembranes were stained with 3,3 -dihexyloxacarbocyanin iodide (DiO6)( g r e e n )
and SAA was labeled with anti-SAA antibodies (red) (c). Merged labeling indicates SAA staining distinct from the endomembranes (b)
and (c). Endoplasmic reticulum is shown by the purple arrows, mitochondrion with the green arrow. HCAEC were stained with DiO6
and show colocalization of SAA with nanotubes (d). SAA was clearly detected at the tips of the ﬁlopodial protrusions (white arrows), and
in vesicles dispersed outside the cells (white arrowheads). The association of SAA with endomembranes remains unclear. Anti-SAA poly-
clonal antibodies 3, 5, and 6, which target SAA peptides with amino acid sequences 27–44, 59–72, and 68–84, respectively, were used in the
designated SAA panels.6 Journal of Biomedicine and Biotechnology
1 23 4 5 6 7 8
12kD
SAA peptide
sequence 1–17 14–30 27–44 40–63 59–72 68–84 79–94 89–104
Figure 3: Multimerization of SAA. Human recombinant SAA was
blotted onto nitrocellulose membranes and overlayed with poly-
clonal antibodies against synthetic SAA human peptides ranging
from the indicated amino acid sequences: lane 1: SAA1–17, lane 2:
SAA14–30, lane 3: SAA27–44, lane 4: SAA40–63, lane 5: SAA59–72,
lane6:SAA68–84,lane7:SAA79–94,andlane8:SAA89–104.HRP-
labeled secondary goat antirabbit antibody was used for secondary
incubation followed by luminol and chemiluminescent detection.
The SAA monomer at around 12kD is indicated.
vinblastine, which disrupts microtubules in cultured embry-
onic ﬁbroblasts [28]. SAA-like material has also been shown
previously to be present intracellularly in cultured human
endothelial cells, speciﬁcally in HUVEC [29]. In that study,
SAA was found to be localized in an irregular ﬁlament-
like staining pattern in the perinuclear regions of HUVEC.
Our results showing colocalization of SAA with micro-
tubules(Figure 1,antitubulinpanels)explaintheperinuclear
concentration of SAA because of the well-known and, in
our ﬁgures, well-documented concentration of microtubules
close to the nucleus. We have previously shown diﬀerential
mRNA expression of SAA in HCAEC versus HUVEC [25],
indicating endothelial cell speciﬁcity.
In our paper (Figures 2(a) and 2(a’)), there is a persistent
immunoﬂuorescent labeling of SAA also observed in the
nucleus of HCAEC that varied considerably among cells,
which could point to an additional role of SAA in the regula-
tionofgeneexpression.AsimilarnucleardistributionofSAA
was found in macrophages where an implication for SAA-
dependent gene regulation was proposed. In this study, SAA
was shown to be uptaken along with HDL in murine macro-
phages. SAA (or its fragments) was detected proceeding the
perinuclear region and further the nucleus [30]. Within
60min, SAA was found in the cytoplasm with subsequent
localization at the plasma membrane and further extrusion
from the cell. This study was the ﬁrst to follow the path
of SAA through a particular cell type. This paper gave the
indication that SAA itself might regulate macrophage gene
regulation. Both murine acute phase isoforms of SAA1.1
and SAA2.1 bind well to the plasma membrane, with only
SAA2.1 taken up by the cell at 37◦Ca n dl a t e rd e t e c t e di nt h e
nucleus. This suggests that the two isoforms have diﬀerential
localizations and distinct physiological roles in cells [30].
This might very well be the case also in humans, and a
moredetailedanalysisoftheSAAisotypesandtheirlocations
within cells would be prudent in the future.
In addition to its putative intracellular functions, SAA
seems to be involved in intercellular communication based
on its location in nanotubes (Figure 2(d)). Intercellular
nanotubes (ICNs) are recently described thin protrusions
that can connect cells which are several cell diameters apart
[31]. Nanotubes are very dynamic structures, involving
motor proteins in molecular cargo transport [32]. The
discovery of SAA localized in nanotubes and their dilatated
regions (Figure 2, bottom micrograph) previously described
as gondolas [26] indicate a possible exchange of SAA
among cells and the role of this molecule in intercellular
communication. Numerous extracellular vesicles (micropar-
ticles or exosomes) containing SAA (possibly arising from
the budding of the plasma membrane) also point to the
proposed role in intercellular communication.
Since SAA has been implicated in host defense, as having
beneﬁcial functions in the protection against microbes [12,
15, 33], we speculate that SAA localization could be an im-
portant additional prerequisite for this process to occur,
especially in epithelial cells. The microtubular association
of SAA in correlation to the recently found microtubular
involvement in bacterial internalization into epithelial cells
[34] points to a possible contribution of microtubules bear-
ing SAA in the epithelial resistance to bacterial infection. In
2002, two groups almost simultaneously reported on acute
phase SAA being able to form channels in planar lipid
bilayermembranesatphysiologicalconcentrationsand,thus,
play a role in host defense, by placing a severe metabolic
strain on bacterial cells [10, 11]. Electron microscopy by
Wang et al. revealed that these channels were formed by
SAA subunits arranged in hexamers, and circular-dichroism
spectrum deconvolution and secondary structure prediction
suggested that SAA contains ∼50% residues in an α-helical
conformation and below 10% in β structure [11]. Later stud-
ies indicated that these hexamers could be totally dissociated
into monomers by urea treatment, with a concerted loss of
its α-helical structure [35]. We have conﬁrmed that, upon
addition of 6M urea to human recombinant SAA, there
is an apparent lack of self-multimerization and only mono-
mers are recognized by anti-SAA antibodies from human
sera on an immunoblot [36]. Since the studies by Wang et al.
[35]wereperformedonmurineSAAandlittleinformationis
available in this regard concerning human SAA, the immun-
oblots we performed (Figure 3 and [36]) indicated that
similar multimerization was occurring for human SAA. No
X-raycrystallographicdataiscurrentlyavailableforSAA,but
it appears that the structure and function of this important
acute phase protein is modulated in vivo upon binding to
apolipoproteins and/or other factors into complexes in
the circulation. Intracellular associations of SAA multimers
within eukaryotic cells have been largely unaddressed; how-
ever, they could provide important clues to how SAA fun-
ctions within these cells and whether its locations are in-
ﬂuenced by these interactions.
5. Conclusion
SAA localizes with microtubules in untreated HCAEC, but
not with actin ﬁlaments or vimentin. These data indicate
that SAA can be attached to microtubules and can possibly
be transported between neighboring cells by means ofJournal of Biomedicine and Biotechnology 7
nanotubesorbuddingvesicles.StainingforSAAisalsofound
in the nucleus which indicates that SAA might have nuclear-
speciﬁc functions.
Intra- and intercellular SAA could play diﬀerent roles in
the physiological state, depending on the environment where
it is located. On the basis of the distribution in endothelial
cells, SAA can be predicted to contribute also to the anti-
bacterial barrier function of this epithelium.
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